Discussion
The experimental therapy brezosiran can reduce levels of the mutant huntingtin protein in people with Huntington’s disease, according to interim data from a small clinical trial. The results were shared in oral and poster presentations at the European Huntington’s Disease Network Clinical Research Congress 2026, held Oct.